SEO URLwww.firestrike.ai/deals/dark-blue-therapeutics-amgen-acquisition-2026-5
acquisitionAnnounced · Jan 7, 2026BiotechSource · CredibleArticle · Factual
Amgen acquires Dark Blue Therapeutics
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$840M
Target
Dark Blue Therapeutics
Acquirer
Amgen
Full Acquisition
Status
Completed
Amgen agreed to acquire Dark Blue Therapeutics. Reported deal value: $840M. Status: Completed. Sector: Biotech. Target headquarters context: Location not specified.
This page summarizes publicly available information about the transaction as of 2026-01-07. Figures and status may change as filings and press coverage update.
Dark Blue Therapeutics , a British discovery and development BioTech company innovating the next generation of precision oncology medicines, has been acquired by US- based global BioTech company Amgen , in a transaction valued at up to € 71 8 million
Deal timeline
Announced
Jan 7, 2026 · eu-startups.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biotech with a reported deal value of $840M. Figures and status may change as sources update.
Sources: eu-startups.com · Primary article · FireStrike proprietary index